India Emerges as a Bioinformatics Powerhouse in Immunotherapy Innovation

India is transitioning from a genomics research participant to a global innovator, thanks to institutional support, a thriving startup ecosystem, and scientific talent. A standout in this shift is Strand Life Sciences, which leverages 25+ years of expertise in (next-generation sequencing) NGS-based assays, multi-omics integration, and bioinformatics pipelines to accelerate therapy development. Advances in CAR-T cell therapies and immune checkpoint inhibitors (ICIs), supported by molecular techniques like NGS, RNA-seq, and CITE-seq, are reshaping cancer treatment. India’s first CAR-T therapy, NexCAR19, approved in 2023, marks a milestone—especially as CAR-T efficacy expands from blood to solid tumours, which account for 90% of all cancers. The recent FDA approval of ICI cosibelimab-ipdl underscores this progress. Bioinformatics is pivotal in decoding gene expression, mapping immune responses, and optimizing therapies. With multi-omics platforms now incorporating epigenomics and spatial transcriptomics, India is at the forefront of transforming personalized cancer care and immunotherapy innovation.

25-07-2025